Log in
NASDAQ:SBBP

Strongbridge Biopharma Stock Forecast, Price & News

$2.76
+0.08 (+2.99 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$2.64
Now: $2.76
$2.77
50-Day Range
$1.89
MA: $2.26
$2.76
52-Week Range
$1.50
Now: $2.76
$4.63
Volume138,500 shs
Average Volume460,379 shs
Market Capitalization$185.59 million
P/E RatioN/A
Dividend YieldN/A
Beta1.72
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company offers Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trials that for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania.
Read More
Strongbridge Biopharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.79 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SBBP
CUSIPN/A
Phone610-254-9200
Employees71

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$21.71 million
Book Value$1.33 per share

Profitability

Net Income$-49,450,000.00
Net Margins-205.02%

Miscellaneous

Market Cap$185.59 million
Next Earnings Date2/23/2021 (Estimated)
OptionableOptionable
$2.76
+0.08 (+2.99 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SBBP News and Ratings via Email

Sign-up to receive the latest news and ratings for SBBP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Strongbridge Biopharma (NASDAQ:SBBP) Frequently Asked Questions

How has Strongbridge Biopharma's stock been impacted by Coronavirus (COVID-19)?

Strongbridge Biopharma's stock was trading at $2.32 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SBBP shares have increased by 19.0% and is now trading at $2.76.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Strongbridge Biopharma?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Strongbridge Biopharma
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Strongbridge Biopharma?

Wall Street analysts have given Strongbridge Biopharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Strongbridge Biopharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Strongbridge Biopharma's next earnings date?

Strongbridge Biopharma is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Strongbridge Biopharma
.

How were Strongbridge Biopharma's earnings last quarter?

Strongbridge Biopharma plc (NASDAQ:SBBP) released its quarterly earnings data on Thursday, October, 29th. The biotechnology company reported ($0.18) EPS for the quarter, topping the Zacks' consensus estimate of ($0.26) by $0.08. The biotechnology company had revenue of $8.07 million for the quarter, compared to analysts' expectations of $7.23 million. Strongbridge Biopharma had a negative net margin of 205.02% and a negative return on equity of 80.86%.
View Strongbridge Biopharma's earnings history
.

What guidance has Strongbridge Biopharma issued on next quarter's earnings?

Strongbridge Biopharma updated its FY 2020 After-Hours earnings guidance on Thursday, October, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $28-29 million, compared to the consensus revenue estimate of $27.8 million.

What price target have analysts set for SBBP?

4 equities research analysts have issued 1 year price targets for Strongbridge Biopharma's shares. Their forecasts range from $5.00 to $10.00. On average, they anticipate Strongbridge Biopharma's share price to reach $7.13 in the next twelve months. This suggests a possible upside of 158.2% from the stock's current price.
View analysts' price targets for Strongbridge Biopharma
.

Who are some of Strongbridge Biopharma's key competitors?

What other stocks do shareholders of Strongbridge Biopharma own?

Who are Strongbridge Biopharma's key executives?

Strongbridge Biopharma's management team includes the following people:
  • Mr. John H. Johnson, Chief Exec. Officer (Age 62, Pay $765.19k)
  • Mr. Robert Matthew Lutz, Chief Financial Officer (Age 51, Pay $543.13k)
  • Mr. Richard S. Kollender CPA, M.B.A., CPA, Chief Operating Officer (Age 51, Pay $50.04k)
  • Dr. Fredric Cohen, Chief Medical Officer (Age 55, Pay $593.89k)
  • Dr. Per Marin M.D., Ph.D., Founder and Sr. Clinical Advisor
  • Mr. Peter J. Valentinsson, Sr. VP of Global Technical Operations
  • Mr. Stephen J. Long, Chief Legal Officer & Company Sec. (Age 54)
  • Mr. Brian Conner, Chief Compliance Officer
  • Mr. Dave Bonnell, Sr. VP of Sales & Marketing
  • Ms. Emily Doyle, Chief HR Officer

What is Strongbridge Biopharma's stock symbol?

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

Who are Strongbridge Biopharma's major shareholders?

Strongbridge Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Caxton Corp (12.03%), Stonepine Capital Management LLC (2.86%), BlackRock Inc. (2.84%), Morgan Stanley (2.82%), Granite Point Capital Management L.P. (1.64%) and State Street Corp (1.08%). Company insiders that own Strongbridge Biopharma stock include Associates LLC Cdk and David N Gill.
View institutional ownership trends for Strongbridge Biopharma
.

Which institutional investors are selling Strongbridge Biopharma stock?

SBBP stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Acadian Asset Management LLC, BlackRock Inc., First Quadrant L P CA, and State Street Corp.
View insider buying and selling activity for Strongbridge Biopharma
.

Which institutional investors are buying Strongbridge Biopharma stock?

SBBP stock was purchased by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Caxton Corp, Granite Point Capital Management L.P., Morgan Stanley, ExodusPoint Capital Management LP, Worth Venture Partners LLC, Wells Fargo & Company MN, and Jane Street Group LLC. Company insiders that have bought Strongbridge Biopharma stock in the last two years include Associates LLC Cdk, and David N Gill.
View insider buying and selling activity for Strongbridge Biopharma
.

How do I buy shares of Strongbridge Biopharma?

Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Strongbridge Biopharma's stock price today?

One share of SBBP stock can currently be purchased for approximately $2.76.

How big of a company is Strongbridge Biopharma?

Strongbridge Biopharma has a market capitalization of $185.59 million and generates $21.71 million in revenue each year. The biotechnology company earns $-49,450,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis. Strongbridge Biopharma employs 71 workers across the globe.

What is Strongbridge Biopharma's official website?

The official website for Strongbridge Biopharma is www.strongbridgebio.com.

How can I contact Strongbridge Biopharma?

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]

This page was last updated on 11/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.